# Socket Mobile, Inc.: financial statements, quarterly

SCKT · Nasdaq · CIK 944075 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sckt.md) · [Financials](/companies/sckt/financials.md) · [Filings](/companies/sckt/filings.md) · [Insiders](/companies/sckt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sckt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.2](/filings/0000944075-24-000083.md) | [4.4 d](/filings/0000944075-25-000013.md) | [5.0](/filings/0000944075-25-000025.md) | [5.1](/filings/0000944075-25-000064.md) | [3.9](/filings/0000944075-25-000083.md) | [4.8 d](/filings/0000944075-26-000027.md) | [4.0](/filings/0000944075-26-000040.md) | [4.0](/filings/0000944075-26-000066.md) | [3.1](/filings/0000944075-25-000083.md) | [4.0 d](/filings/0000944075-26-000027.md) | [3.7](/filings/0000944075-26-000040.md) | [3.0](/filings/0000944075-26-000066.md) |
| Cost of revenue | $m | [1.8](/filings/0000944075-24-000083.md) | [2.1 d](/filings/0000944075-25-000013.md) | [2.5](/filings/0000944075-25-000025.md) | [2.5](/filings/0000944075-25-000064.md) | [2.0](/filings/0000944075-25-000083.md) | [2.4 d](/filings/0000944075-26-000027.md) | [2.0](/filings/0000944075-26-000040.md) | [2.0](/filings/0000944075-26-000066.md) | [1.6](/filings/0000944075-25-000083.md) | [2.0 d](/filings/0000944075-26-000027.md) | [1.8](/filings/0000944075-26-000040.md) | [1.6](/filings/0000944075-26-000066.md) |
| Gross profit | $m | [1.4](/filings/0000944075-24-000083.md) | [2.3 d](/filings/0000944075-25-000013.md) | [2.5](/filings/0000944075-25-000025.md) | [2.6](/filings/0000944075-25-000064.md) | [1.9](/filings/0000944075-25-000083.md) | [2.5 d](/filings/0000944075-26-000027.md) | [2.0](/filings/0000944075-26-000040.md) | [2.0](/filings/0000944075-26-000066.md) | [1.5](/filings/0000944075-25-000083.md) | [2.0 d](/filings/0000944075-26-000027.md) | [1.9](/filings/0000944075-26-000040.md) | [1.4](/filings/0000944075-26-000066.md) |
| Research and development | $m | [1.2](/filings/0000944075-24-000083.md) | [1.2 d](/filings/0000944075-25-000013.md) | [1.2](/filings/0000944075-25-000025.md) | [1.2](/filings/0000944075-25-000064.md) | [1.2](/filings/0000944075-25-000083.md) | [1.1 d](/filings/0000944075-26-000027.md) | [1.1](/filings/0000944075-26-000040.md) | [1.1](/filings/0000944075-26-000066.md) | [1.0](/filings/0000944075-25-000083.md) | [1.1 d](/filings/0000944075-26-000027.md) | [1.1](/filings/0000944075-26-000040.md) | [1.1](/filings/0000944075-26-000066.md) |
| Operating income | $m | [(1.4)](/filings/0000944075-24-000083.md) | [(0.5) d](/filings/0000944075-25-000013.md) | [(0.5)](/filings/0000944075-25-000025.md) | [(0.5)](/filings/0000944075-25-000064.md) | [(1.0)](/filings/0000944075-25-000083.md) | [(0.4) d](/filings/0000944075-26-000027.md) | [(0.9)](/filings/0000944075-26-000040.md) | [(0.7)](/filings/0000944075-26-000066.md) | [(1.1)](/filings/0000944075-25-000083.md) | [(0.6) d](/filings/0000944075-26-000027.md) | [(0.8)](/filings/0000944075-26-000040.md) | [(1.2)](/filings/0000944075-26-000066.md) |
| Interest expense | $m | [0.1](/filings/0000944075-24-000083.md) | [(0.4) d](/filings/0000944075-25-000013.md) | [(0.1)](/filings/0000944075-25-000025.md) | [(0.1)](/filings/0000944075-25-000064.md) | [(0.1)](/filings/0000944075-25-000083.md) | [(0.1) d](/filings/0000944075-26-000027.md) | [(0.1)](/filings/0000944075-26-000040.md) | [(0.1)](/filings/0000944075-26-000066.md) | [(0.1)](/filings/0000944075-25-000083.md) | [(0.1) d](/filings/0000944075-26-000027.md) | [(0.1)](/filings/0000944075-26-000040.md) | [(0.2)](/filings/0000944075-26-000066.md) |
| Income tax | $m | [(0.2)](/filings/0000944075-24-000083.md) | [1.4 d](/filings/0000944075-25-000013.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(1.3)](/filings/0000944075-24-000083.md) | [0.9 d](/filings/0000944075-25-000013.md) | [(0.6)](/filings/0000944075-25-000083.md) | [(0.6)](/filings/0000944075-25-000083.md) | [(1.1)](/filings/0000944075-25-000083.md) | [0.0 d](/filings/0000944075-26-000027.md) | [(1.0)](/filings/0000944075-26-000066.md) | [(0.8)](/filings/0000944075-26-000066.md) | [(1.2)](/filings/0000944075-25-000083.md) | [(11.4) d](/filings/0000944075-26-000027.md) | [(0.9)](/filings/0000944075-26-000066.md) | [(1.3)](/filings/0000944075-26-000066.md) |
| Diluted EPS | $ per share | [(0.18)](/filings/0000944075-24-000083.md) | not reported | [(0.07)](/filings/0000944075-25-000025.md) | [(0.08)](/filings/0000944075-25-000064.md) | [(0.15)](/filings/0000944075-25-000083.md) | not reported | [(0.13)](/filings/0000944075-26-000040.md) | [(0.10)](/filings/0000944075-26-000066.md) | [(0.15)](/filings/0000944075-25-000083.md) | not reported | [(0.11)](/filings/0000944075-26-000040.md) | [(0.16)](/filings/0000944075-26-000066.md) |
| Basic EPS | $ per share | [(0.18)](/filings/0000944075-24-000083.md) | not reported | [(0.07)](/filings/0000944075-25-000025.md) | [(0.08)](/filings/0000944075-25-000064.md) | [(0.15)](/filings/0000944075-25-000083.md) | not reported | [(0.13)](/filings/0000944075-26-000040.md) | [(0.10)](/filings/0000944075-26-000066.md) | [(0.15)](/filings/0000944075-25-000083.md) | not reported | [(0.11)](/filings/0000944075-26-000040.md) | [(0.16)](/filings/0000944075-26-000066.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.1](/filings/0000944075-23-000087.md) | [2.8](/filings/0000944075-25-000083.md) | [2.8](/filings/0000944075-25-000025.md) | [2.1](/filings/0000944075-25-000064.md) | [2.9](/filings/0000944075-25-000083.md) | [2.5](/filings/0000944075-26-000066.md) | [1.7](/filings/0000944075-26-000040.md) | [2.6](/filings/0000944075-26-000066.md) | [2.0](/filings/0000944075-25-000083.md) | [2.0](/filings/0000944075-26-000066.md) | [1.7](/filings/0000944075-26-000040.md) | [1.6](/filings/0000944075-26-000066.md) |
| Current assets | $m | [11.0](/filings/0000944075-23-000087.md) | [10.7](/filings/0000944075-25-000013.md) | [11.0](/filings/0000944075-24-000026.md) | [10.7](/filings/0000944075-24-000053.md) | [10.3](/filings/0000944075-24-000083.md) | [9.6](/filings/0000944075-26-000027.md) | [9.8](/filings/0000944075-25-000025.md) | [9.9](/filings/0000944075-25-000064.md) | [8.9](/filings/0000944075-25-000083.md) | [8.6](/filings/0000944075-26-000066.md) | [8.5](/filings/0000944075-26-000040.md) | [7.3](/filings/0000944075-26-000066.md) |
| Total assets | $m | [27.3](/filings/0000944075-23-000087.md) | [28.7](/filings/0000944075-25-000013.md) | [28.7](/filings/0000944075-24-000026.md) | [28.0](/filings/0000944075-24-000053.md) | [27.7](/filings/0000944075-24-000083.md) | [27.3](/filings/0000944075-26-000027.md) | [27.2](/filings/0000944075-25-000025.md) | [27.0](/filings/0000944075-25-000064.md) | [25.6](/filings/0000944075-25-000083.md) | [14.4](/filings/0000944075-26-000066.md) | [13.9](/filings/0000944075-26-000040.md) | [12.4](/filings/0000944075-26-000066.md) |
| Current liabilities | $m | [6.0](/filings/0000944075-23-000087.md) | [6.5](/filings/0000944075-25-000013.md) | [6.8](/filings/0000944075-24-000026.md) | [6.6](/filings/0000944075-24-000053.md) | [7.3](/filings/0000944075-24-000083.md) | [6.9](/filings/0000944075-26-000027.md) | [7.8](/filings/0000944075-25-000025.md) | [8.3](/filings/0000944075-25-000064.md) | [8.1](/filings/0000944075-25-000083.md) | [8.4](/filings/0000944075-26-000066.md) | [8.8](/filings/0000944075-26-000040.md) | [8.5](/filings/0000944075-26-000066.md) |
| Total liabilities | $m | [8.9](/filings/0000944075-23-000087.md) | [9.3](/filings/0000944075-25-000013.md) | [9.5](/filings/0000944075-24-000026.md) | [9.2](/filings/0000944075-24-000053.md) | [9.8](/filings/0000944075-24-000083.md) | [9.2](/filings/0000944075-26-000027.md) | [9.9](/filings/0000944075-25-000025.md) | [10.3](/filings/0000944075-25-000064.md) | [10.0](/filings/0000944075-25-000083.md) | [10.2](/filings/0000944075-26-000066.md) | [10.4](/filings/0000944075-26-000040.md) | [10.0](/filings/0000944075-26-000066.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [18.4](/filings/0000944075-24-000083.md) | [19.4](/filings/0000944075-26-000027.md) | [19.2](/filings/0000944075-25-000083.md) | [18.8](/filings/0000944075-25-000083.md) | [18.0](/filings/0000944075-25-000083.md) | [18.2](/filings/0000944075-26-000066.md) | [17.2](/filings/0000944075-26-000066.md) | [16.7](/filings/0000944075-26-000066.md) | [15.7](/filings/0000944075-25-000083.md) | [4.3](/filings/0000944075-26-000066.md) | [3.5](/filings/0000944075-26-000066.md) | [2.4](/filings/0000944075-26-000066.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [5.7 d](/filings/0000944075-24-000083.md) | [571 d](/filings/0000944075-25-000013.md) | [(94.9)](/filings/0000944075-25-000025.md) | [(544) d](/filings/0000944075-25-000064.md) | [204 d](/filings/0000944075-25-000083.md) | [(87.0) d](/filings/0000944075-26-000027.md) | [(733)](/filings/0000944075-26-000040.md) | [(464) d](/filings/0000944075-26-000066.md) | [(403) d](/filings/0000944075-25-000083.md) | [350 d](/filings/0000944075-26-000027.md) | [(769)](/filings/0000944075-26-000040.md) | [136 d](/filings/0000944075-26-000066.md) |
| Capital expenditure | $k | [366 d](/filings/0000944075-24-000083.md) | [695 d](/filings/0000944075-25-000013.md) | [56.4](/filings/0000944075-25-000025.md) | [111 d](/filings/0000944075-25-000064.md) | [397 d](/filings/0000944075-25-000083.md) | [224 d](/filings/0000944075-26-000027.md) | [52.3](/filings/0000944075-26-000040.md) | [137 d](/filings/0000944075-26-000066.md) | [187 d](/filings/0000944075-25-000083.md) | [161 d](/filings/0000944075-26-000027.md) | [53.3](/filings/0000944075-26-000040.md) | [90.7 d](/filings/0000944075-26-000066.md) |
| Share repurchases | $k | [0.0 d](/filings/0000944075-24-000083.md) | [0.0 d](/filings/0000944075-25-000013.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [7,153](/filings/0000944075-23-000087.md) | [7,107](/filings/0000944075-24-000026.md) | [7,164](/filings/0000944075-24-000053.md) | [7,320](/filings/0000944075-24-000083.md) | [7,442](/filings/0000944075-25-000025.md) | [7,572](/filings/0000944075-25-000064.md) | [7,601](/filings/0000944075-25-000083.md) | [7,829](/filings/0000944075-26-000040.md) | [7,937](/filings/0000944075-26-000066.md) | [7,961](/filings/0000944075-25-000083.md) | [8,136](/filings/0000944075-26-000040.md) | [8,245](/filings/0000944075-26-000066.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,291,681 at 2026-08-10, from the cover of the [10-Q filed 2026-08-13](/filings/0000944075-26-000066.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.